Trial Profile
Phase IB open label study to assess the safety, pharmacokinetics and clinical activity of Acelarin (NUC-1031) given on days 1 & 8 with carboplatin on day 1, every three weeks for 6 cycles in participants diagnosed with recurrent ovarian cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fosgemcitabine palabenamide (Primary) ; Carboplatin
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms ProGem2
- 19 Mar 2021 Results published in the Clinical Cancer Research
- 04 Jun 2019 Results assessing the anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent using PRO-002 and ABC-08 trial presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.